Baseline Laboratory Testing Before Starting Biktarvy
Before initiating Biktarvy, you must obtain hepatitis B virus (HBV) testing, serum creatinine with estimated creatinine clearance, urine glucose, and urine protein; additionally, check serum phosphorus in patients with chronic kidney disease. 1
Required Testing
The FDA label explicitly mandates specific baseline assessments 1:
Hepatitis B Testing
- HBV surface antigen (HBsAg) is required prior to or when initiating Biktarvy
- This is critical because discontinuing the emtricitabine and tenofovir components can cause severe acute exacerbations of hepatitis B in coinfected patients
- The boxed warning emphasizes this risk, requiring close hepatic monitoring for months after discontinuation if HBV coinfection exists
Renal Function Assessment
- Serum creatinine and estimated creatinine clearance (eCrCl)
- Urine glucose and urine protein in all patients
- Serum phosphorus specifically in patients with pre-existing chronic kidney disease
- These tests should be performed "prior to or when initiating" and repeated during treatment as clinically appropriate
Important caveat: Bictegravir causes small increases in serum creatinine (0.1-0.15 mg/dL) by inhibiting tubular secretion without affecting actual glomerular filtration rate 2. This is a benign pharmacologic effect, not true renal toxicity. However, baseline assessment is still required to establish a new baseline and ensure eCrCl ≥30 mL/min for standard dosing.
Additional Recommended Testing
While not explicitly mandated by the FDA label, current guidelines 3 and clinical practice support obtaining:
HIV-Specific Parameters
- HIV-1 RNA (viral load) - to establish baseline and monitor response
- CD4+ T-cell count - for staging and monitoring, though not required to delay treatment
- HIV genotypic resistance testing - ideally obtained, but should not delay treatment initiation in most cases 3
The 2025 IAS-USA guidelines 3 explicitly state that Biktarvy can be started in persons who acquired HIV while on PrEP before resistance testing results are available, with adjustment based on results when they return.
Other Baseline Labs
- Complete blood count (CBC) - though hematologic toxicity is rare with Biktarvy 2
- Hepatic transaminases (ALT/AST) - baseline liver function, though routine monitoring after initiation is not evidence-based 2
- Lipid panel - for cardiovascular risk assessment, though Biktarvy has minimal lipid effects 2
- Hemoglobin A1C or fasting glucose - for diabetes screening
- Pregnancy test in persons of childbearing potential
Rapid Start Considerations
Biktarvy is particularly well-suited for rapid ART initiation because it does not require HLA-B*5701 testing (unlike abacavir-containing regimens) 3, 4. Multiple studies demonstrate that Biktarvy can be safely initiated at the first specialist visit without waiting for all baseline laboratory results 5, 6, 7.
In the BIFAST study 5, initiating Biktarvy immediately without baseline data achieved 84.8% viral suppression at week 48 with only one Grade 1 adverse event leading to discontinuation. The median time from diagnosis to treatment was reduced from 3.9 weeks to 2.4 weeks (p=0.015).
The only absolute contraindication requiring baseline testing is severe renal impairment (eCrCl 15-29 mL/min) or end-stage renal disease not on hemodialysis 1. Therefore, at minimum, you need a creatinine to calculate eCrCl before prescribing.
Clinical Algorithm
Obtain immediately (same day if possible):
- HBV surface antigen
- Serum creatinine (calculate eCrCl)
- Urine glucose and protein
- Pregnancy test if applicable
Start Biktarvy once eCrCl ≥30 mL/min confirmed - do not wait for other results
Obtain within first week but do not delay treatment:
- HIV-1 RNA
- CD4+ count
- HIV genotype
- CBC, hepatic panel, lipids, A1C
Add serum phosphorus if chronic kidney disease present
Adjust therapy only if resistance mutations detected or HBV coinfection requires specific management considerations